Risk of cancer after lumbar fusion surgery with recombinant human bone morphogenic protein-2 (rh-BMP-2)

Spine

Volumn 38, Issue 21, 2013, Pages 1862-1868

  Cooper, Gregory S ^a   Kou, Tzuyung Doug ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Recombinant human bone morphogenic

Indexed keywords

BONE MORPHOGENETIC PROTEIN; RECOMBINANT HUMAN BONE MORPHOGENIC PROTEIN 2; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; BILE DUCT CARCINOMA; BLADDER CANCER; BONE CANCER; BRAIN CANCER; BREAST CANCER; BRONCHUS CANCER; CANCER DIAGNOSIS; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; KAPOSI SARCOMA; KIDNEY CANCER; KIDNEY PELVIS CANCER; LARYNX CANCER; LEUKEMIA; LIVER CANCER; LUMBAR SPINE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MESOTHELIOMA; MOUTH CANCER; MYELOMA; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PHARYNX CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SPINE FUSION; STOMACH CANCER; TESTIS CANCER; THYROID CANCER; UTERUS CANCER;

AGED; AGED, 80 AND OVER; BONE MORPHOGENETIC PROTEIN 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUMBAR VERTEBRAE; MALE; MEDICARE; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); PROPORTIONAL HAZARDS MODELS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SPINAL FUSION; UNITED STATES;

EID: 84888644416     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e3182a3d3b4     Document Type: Article

References (21)

1. Rihn JA, Gates C, Glassman SD, et al. The use of bone morphogenic protein in lumbar spine surgery . J Bone Joint Surg Am 2008; 90 : 2014 - 25 .
2. Thawani JP, Wang AC, Than KD, et al. Bone morphogenic proteins and cancer: review of the literature . Neurosurgery 2010; 66 : 233 - 46 .
3. Benglis D, Wang MY, Levi AD . A comprehensive review of the safety profi le of bone morphogenic protein in spine surgery . Neurosurgery 2008; 62 : ONS423 - 31 .
4. Poynton AR, Lane JM . Safety profi le for the clinical use of bone morphogenic proteins in the spine . Spine 2002; 27 ( suppl ): S40 - 8 .
5. Mines D, Gu Y, Kou TD, et al . Recombinant human bone morphogenic protein-2 and pancreatic cancer: A retrospective cohort study . Pharmacoepid Drug Saf 2011; 20 : 111 - 8 .
6. Simmonds MC, Brown JVE, Heirs MK, et al. Safety and effectiveness of recombinant human bone morphogenic protein-2 for spinal fusion . Ann Intern Med 2013; 158 : 877 - 89 .
7. Fu R, Selph S, McDonagh M, et al. Effectiveness and harms of recombinant human bone morphogenic protein-2 in spine fusion . Ann Intern Med 2013; 158 : 890 - 902 .
8. Howlader N, Noone AM, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations).
9. Bethesda, MD: National Cancer Institute; 2011 . http://seer.cancer.gov/ csr/1975-2009-pops09/. SEER data submission, posted to the SEER Web site. Accessed April 2012.
10. Klabunde CN, Warren JL, Legler JM . Assessing comorbidity using claims data . Med Care 2002; 40 ( suppl ): 26 - 35 .
11. Carragee EJ, Hurwitz EL, Weiner BK . A critical review of recombinant human bone morphogenic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned . Spine J 2011; 11 : 471 - 91 .
12. Valdes MA, Thakur NA, Namdari S, et al. Recombinant bone morphogenic protein-2 in orthopaedic surgery: A review . Arch Orthop Trauma Surg 2009; 129 : 1651 - 7 .
13. Glassman SD, Howard J, Dimar J, et al. Complications with recombinant human bone morphogenic protein-2 in posterolateral spine fusion . Spine 2011; 36 : 1849 - 54 .
14. Langenfeld EM, Langenfeld J . Bone morphogenic protein-2 stimulates angiogenesis in developing tumors . Mol Cancer Res 2004; 2 : 141 - 9 .
15. Bieniasz M, Oszajca K, Eusebio M, et al. The positive correlation between gene expression of the two angiogenic factors: VEGF and BMP-2 in lung cancer patients . Lung Cancer 2009; 66 : 319 - 26 .
16. Kleeff J, Maruyama H, Ishiwata T, et al. Bone morphogenic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo . Gastroenterology 1999; 116 : 1202 - 16 .
17. Singh A, Morris RJ . The Yin and Yang of bone morphogenic proteins in cancer . Cytokine Growth Factor Rev 2010; 21 : 299 - 313 .
18. Soda H, Raymond E, Sharma S, et al. Antiproliferative effects of recombinant human bone morphogenic protein-2 on human tumor colony-forming units . Anticancer Drugs 1998; 9 : 327 - 31 .
19. Piccirillo SG, Reynolds BA, Zanetti N, et al. Bone morphogenic proteins inhibit the tumorigenic potential of human brain tumorinitiating cells . Nature 2006; 444 : 761 - 5 .
20. Hallahan AR, Pritchard JI, Chandraratna RA, et al. BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect . Nat Med 2003; 9 : 1033 - 8 .
21. Infuse Bone Graft : Brief summary of indications, contraindications and warnings . https://www.infusebonegraft.com/infuse-indications.html. Accessed July 29, 2013.